KIT and chronic myelogenous leukemia, BCR-ABL1 positive: HHT, a recognized protein synthesis inhibitor, playing a significant role in the treatment of hematological diseases such as AML, CML, MDS, and polycythemia vera by regulating mechanisms including KIT, MYC, MCL-1 and Cyclin-D1 [27–29].